Resources from the same session
176MO - Low-dose computed tomography lung cancer screening participants live longer than matched controls: A population-based study
Presenter: Robert Dziedzic
Session: Mini Oral session 3
Resources:
Abstract
Slides
Webcast
177MO - Cardiovascular assessment in lung cancer screening: Initial findings from the European 4-IN-THE-LUNG-RUN trial
Presenter: Daiwei Han
Session: Mini Oral session 3
Resources:
Abstract
Q&A
Session: Mini Oral session 3
Resources:
Webcast
195MO - Tarlatamab in previously treated small cell lung cancer (SCLC): DeLLphi-300 phase I study long-term outcomes and intracranial activity
Presenter: Horst-Dieter Hummel
Session: Mini Oral session 3
Resources:
Abstract
Slides
Webcast
196MO - Anlotinib plus etoposide/carboplatin (EC) versus placebo plus EC in first-line therapy for extensive-stage small cell lung cancer (ES-SCLC): A randomized, double-blind, parallel controlled, phase III trial (ETER 701)
Presenter: Ying Cheng
Session: Mini Oral session 3
Resources:
Abstract
197MO - Final outcome, immunophenotypic and biomarker analysis of intercalated avelumab plus platinum-based chemotherapy in patients with extensive-stage small cell lung cancer (PAVE): A pilot phase II study of the Hellenic co-operative oncology group
Presenter: Giannis Mountzios
Session: Mini Oral session 3
Resources:
Abstract
Slides
Webcast
Invited Discussant 195MO, 196MO and 197MO
Presenter: Jessica Menis
Session: Mini Oral session 3
Resources:
Slides
Webcast
Q&A
Session: Mini Oral session 3
Resources:
Webcast